NasdaqGS:VIRBiotechs
Why Vir Biotechnology (VIR) Is Up 5.1% After Astellas Cancer Deal And Equity Raise News
In late February 2026, Vir Biotechnology announced a global collaboration with Astellas Pharma around its investigational prostate cancer therapy VIR-5500, alongside positive early Phase 1 data, a US$150,000,002 follow-on equity raise, new shelf registration and its 2025 earnings results.
Together, the Astellas partnership economics, encouraging early VIR-5500 data and fresh equity capital appear to materially reshape Vir Biotechnology’s funding mix, oncology profile and long-term...